Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03461458 · ClinicalTrials.gov registry record · Phase 1
Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease
A Phase 1 study, sponsored by Mayo Clinic.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT03461458: Clinical Trial Phase 1 study, sponsored by Mayo Clinic.
NCT03461458 is a Phase 1 study that was terminated before completion, run by Mayo Clinic. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03461458, a Phase 1 study, was terminated before completion, sponsored by Mayo Clinic.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
To determine the safety and feasibility of autologous, culture-expanded adipose-derived (AD) mesenchymal stromal cells (MSCs) in subjects with painful degenerative disc disease (DDD).
Primary Outcome
An adverse event is 1) Defined as any untoward or undesirable medical occurrence in the form of signs, symptoms, abnormal findings, or diseases that emerge or worsen relative to baseline during the study regardless of causal relationship.
Interventions
- DRUG Autologous Adipose-Derived Mesenchymal Stromal Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2018-10-17 |
| Est. Completion | 2021-02-06 |
| Phase | Phase 1 |
Why NCT03461458 stopped before completion
NCT03461458 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Autologous Adipose-Derived Mesenchymal Stromal Cells is the first listed.
NCT03461458 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03461458 about?
NCT03461458 is a clinical study titled "Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease". To determine the safety and feasibility of autologous, culture-expanded adipose-derived (AD) mesenchymal stromal cells (MSCs) in subjects with painful degenerative disc disease (DDD).
What is the current status of trial NCT03461458?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2018-10-17. Estimated completion is 2021-02-06.
What interventions are being tested in trial NCT03461458?
The interventions under investigation include: Autologous Adipose-Derived Mesenchymal Stromal Cells (DRUG).
Who is sponsoring clinical trial NCT03461458?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03461458's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI